Full results from two Lilly trials of the novel triple hormone receptor agonist show reductions in A1c, osteoarthritis knee pain, and obstructive sleep apnea.

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Read clinically focused news coverage of key developments from ADA 2026.

Patients with RA have a higher risk of blood clots and serious infections with baricitinib vs older biologics, but not heart disease or cancer, according to two safety trials.

Cigarette smokers have a significantly lower likelihood of being diagnosed with Sjögren's disease, with histologic data showing less tissue damage and lower disease activity in smokers who have it.

No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide.

Chinese herb-derived compound tetrandrine shows signs of efficacy in methotrexate-treated patients with moderate to severe rheumatoid arthritis, but placebo rates are high.

Amylin, a pancreatic peptide hormone, is involved in the regulation of blood glucose as well as appetite; therefore, long-acting amylin analogs have gained increasing interest as monotherapy, and in ...

Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

Low-dose naltrexone does not provide real clinical benefit for patients with fibromyalgia compared to placebo, according to a clinical trial.

Emerging research says the steroids aren’t a major driver of gestational diabetes, but impacts vary depending on the patient.

Metabolic-bariatric surgery in older adults is effective for long-term weight loss and remission of related medical conditions.